Re: CD-20 on Marmosets

From: Mario Roederer (roederer@drmr.com)
Date: Tue Aug 07 2001 - 14:27:55 EST


Sam,

Most likely this is a titration (affinity) issue.  The CD20 clone
(L27) is very low affinity... meaning that the more you add, or the
longer you wait, or the warmer temp you use for staining, the more
intensity you will see.  This is true on human cells:  I was unable
to saturate CD20 staining even by using very high concentrations of
the antibody (for which you need to get highly concentrated
conjugated antibody).  This is not something specific to the BD clone
of anti-CD20--I've seen it with multiple other clones as well.

My guess is that on the NHP cells, this problem is exacerbated.  I
would recommend trying a staining where you use as high a
concentration of antibody as possible (i.e., resuspend the cells in
neat undiluted antibody, incubate for a while before adding other
antibodies).  In addition, trying staining at room temp or even at
37C to increase the binding rate.  Finally, try staining for a much
longer period of time (30-60 min) than you might otherwise.  If these
steps help, then you are facing the affinity problem.

While I agree that the various online NHP cross-reactivity sites are
very helpful, one thing that is missing is some sort of relative
avidity information.  It's quite possible that some antibodies
labeled as non-cross-reactive actually would work at much higher
concentrations; likewise, it's even possible that some antibodies
could be used at significantly lower concentrations.  We are in the
process of titrating all of our reagents on both human and macaque to
address these issues.

I would encourage everyone to do the same--titrate your antibodies
(on the same day, with the same concentration and incubation
conditions) on both human and NHP cells.  Then we can start reporting
"relative avidity" and "relative saturating fluorescence intensity"
information which will be highly useful to everyone doing NHP
studies.  This information is far more useful than the simple
assertion that the antibodies do, or do not, cross-react.  In
particular, for example, where the cross-reactivity is seen but the
avidity is much lower, researchers would know to alter incubation
conditions (or to only use very bright conjugates like PE).

I hope that the cross-reactivity sites (like Harvard's) will soon
include this kind of information.

mr



This archive was generated by hypermail 2b29 : Sun Jan 05 2003 - 19:01:27 EST